Becton Dickinson & Co Stock Price, News & Analysis

BD (NYSE: BDX) announced the launch of the BD Rhapsody™ HT Xpress System designed for single-cell multiomics analysis, enabling researchers to conduct high-throughput studies with improved sample integrity. This new system can analyze up to eight times more cells than previous models, allowing simultaneous analysis of various cell types like stem and cancer cells. The system will be showcased at the AGBT General Meeting from February 6-9, 2023, in Hollywood, Florida. Additionally, BD is introducing the BD Rhapsody™ Mouse TCR/BCR Multiomic Assay and BD® Flex Single-Cell Multiplexing Kits to enhance data collection capabilities.

BD (Becton, Dickinson and Company) reported first-quarter fiscal 2023 revenues of $4.6 billion, a 2.8% decline year-over-year, while base business revenue increased by 0.4%. Diluted EPS decreased to $1.70 from $1.90, and adjusted diluted EPS fell to $2.98 from $3.17. Despite these declines, the company raised its full-year revenue guidance to $19.1 billion - $19.3 billion and adjusted EPS to $12.07 - $12.32, indicating resilience and strong execution of its BD 2025 strategy. The outlook anticipates continued currency-neutral growth of 5.75% - 6.75% in its base business.

BD (NYSE: BDX) has released its 2022 Cybersecurity Annual Report, emphasizing the company's commitment to enhancing cybersecurity measures in healthcare. The report focuses on transparency and collaboration, detailing efforts to protect patient safety and privacy amidst rising cyber threats like ransomware and phishing. Key highlights include BD's coordinated vulnerability disclosure processes, collaborations with cybersecurity working groups, and proactive measures against emerging risks. The report aims to empower customers by providing essential information on managing cyber risks effectively.

The Board of Directors of Becton, Dickinson and Company (NYSE: BDX) has declared a quarterly dividend of $0.91 per common share, scheduled for payment on March 31, 2023. This will benefit shareholders on record as of March 10, 2023, translating to an indicated annual dividend rate of $3.64 per share. BD remains a leader in global medical technology, focusing on enhancing health through improved medical discovery and diagnostics, serving healthcare providers worldwide.

BD (Becton, Dickinson and Company) has launched the 3rd Generation BD Kiestra™ Total Lab Automation System, designed to enhance laboratory efficiency and flexibility. This new robotic track system automates lab specimen processing, aiming to reduce manual tasks and turnaround times. The system features customizable configurations to fit various laboratory workflows and spaces, utilizing BD Synapsys™ informatics for integrated data analysis. Notable improvements include eliminating manual sorting and optimizing workflows, potentially impacting productivity positively.

BD (Becton, Dickinson and Company) has received Emergency Use Authorization (EUA) from the FDA for a new molecular PCR assay to detect the Mpox virus. This authorization allows the BD MAX™ System users to conduct timely diagnostics, enhancing the ability to combat the Mpox outbreak, designated a global health emergency by the WHO. The BD MAX™ System can process up to 24 samples in under three hours, offering multiple tests for various infections. This development is part of BD's commitment to improving diagnostics and healthcare delivery.

BD (Becton, Dickinson and Company) will host a live webcast of its Annual Meeting of Shareholders on January 24, 2023, at 1 p.m. (ET). Investors can access the webcast via the BD investor relations website, and a replay will be available afterward. BD is a leading global medical technology company focused on improving health outcomes through innovative technology and solutions. The company has a workforce of 77,000 and operates worldwide to address critical global health issues.

BD (Becton, Dickinson and Company) has appointed Michelle Quinn as acting general counsel effective February 3, 2023. She succeeds Samrat Khichi, who is leaving for a new opportunity. Quinn has been with BD since 2019, serving as senior vice president and chief ethics officer. She will lead BD's Law Group and is expected to contribute to the company’s 2025 strategy. In related changes, Ami Simunovich and Chris DelOrefice will oversee new responsibilities, reporting directly to BD’s CEO, Tom Polen.

BD (Becton, Dickinson and Company) will release its financial results for the first quarter of fiscal year 2023 on February 2, 2023, at 6:30 a.m. ET. The results will cover the quarter ending on December 31, 2022, and will be available on their investor relations website. Following the release, management will host an audio webcast at 8 a.m. ET on the same day to discuss the financial results and company strategy. BD is recognized as a leading global medical technology company committed to enhancing healthcare through innovative solutions.